PMSN.F Stock Overview
Provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Proteome Sciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.027 |
| 52 Week High | UK£0.084 |
| 52 Week Low | UK£0.018 |
| Beta | 0.13 |
| 11 Month Change | 8.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -61.43% |
| 5 Year Change | -18.18% |
| Change since IPO | -98.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| PMSN.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 35.0% | -2.3% | 0.3% |
| 1Y | n/a | 3.1% | 31.1% |
Return vs Industry: Insufficient data to determine how PMSN.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how PMSN.F performed against the US Market.
Price Volatility
| PMSN.F volatility | |
|---|---|
| PMSN.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PMSN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PMSN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 35 | Mariola Sohngen | www.proteomics.com |
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates.
Proteome Sciences plc Fundamentals Summary
| PMSN.F fundamental statistics | |
|---|---|
| Market cap | US$10.22m |
| Earnings (TTM) | -US$5.14m |
| Revenue (TTM) | US$5.08m |
2.0x
P/S Ratio-2.0x
P/E RatioIs PMSN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMSN.F income statement (TTM) | |
|---|---|
| Revenue | UK£4.04m |
| Cost of Revenue | UK£3.95m |
| Gross Profit | UK£85.00k |
| Other Expenses | UK£4.16m |
| Earnings | -UK£4.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 2.11% |
| Net Profit Margin | -101.07% |
| Debt/Equity Ratio | -221.8% |
How did PMSN.F perform over the long term?
See historical performance and comparison